Teva Pharmaceutical Industries
TEVA
508 hedge funds and large institutions have $11.2B invested in Teva Pharmaceutical Industries in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 129 increasing their positions, 206 reducing their positions, and 125 closing their positions.
58% more capital inflows, than outflows
Capital inflows: $2.07B | Capital outflows: $1.31B
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
4.89% more ownership
Funds ownership: 48.96% → 53.85% (+4.9%)
5% less funds holding
Funds holding: 536 → 508 (-28)
23% less call options, than puts
Call options by funds: $624M | Put options by funds: $815M
37% less repeat investments, than reductions
Existing positions increased: 129 | Existing positions reduced: 206
62% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 125
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$431M |
| 2 |
Berkshire Hathaway
Omaha,
Nebraska
|
+$284M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$186M |
| 4 |
Brahman Capital
New York
|
+$150M |
| 5 |
Highfields Capital Management
Boston,
Massachusetts
|
+$138M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$193M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$150M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$82M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$76.1M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$63.9M |
TEVA Hedge Fund Activity: Q4 2017 in Review
508 of the 4,418 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceutical Industries (TEVA) for Q4 2017, worth a combined $11.2B — up 18% from $9.5B a quarter earlier.
Sellers outnumbered buyers: 125 funds closed out of TEVA and 47 opened new positions — a net loss of 78 holders — while 206 trimmed existing stakes and 129 added.
The largest buyer was Capital Research Global Investors, adding an estimated $431M. The largest seller was Bank of New York Mellon, cutting an estimated $193M.
- 508 institutional investors held Teva Pharmaceutical Industries (TEVA) as of Q4 2017, down from 536 in Q3 2017.
- Funds reported $11.2B of Teva Pharmaceutical Industries stock for Q4 2017, up 18% quarter-over-quarter.
- 47 funds opened new Teva Pharmaceutical Industries positions in Q4 2017 and 125 closed out, a net change of -78 holders.
- The largest Teva Pharmaceutical Industries buyer in Q4 2017 was Capital Research Global Investors, an estimated $431M added.
- The largest Teva Pharmaceutical Industries seller in Q4 2017 was Bank of New York Mellon, an estimated $193M sold.
Based on aggregated 13F filings for Q4 2017.